A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. - Wikidata - awgldk - TriplyDB

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

http://www.wikidata.org/entity/Q34628840

about

Targeted therapies in sarcomas: challenging the challenge Pazopanib in the management of advanced soft tissue sarcomas Osteosarcoma: Current Treatment and a Collaborative Pathway to Success Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Advances in the management of osteosarcoma Review of Osteosarcoma and Current Management Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series Exploring targeted therapy of osteosarcoma using proteomics data Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.A case report of apatinib in treating osteosarcoma with pulmonary metastases.Osteosarcoma Overview.Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.Treatment pathway of bone sarcoma in children, adolescents, and young adults Animal models in osteosarcoma.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis RPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis.Emerging therapeutic targets for synovial sarcoma.Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.New systemic therapy options for advanced sarcomas.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Promise and pitfalls of quantitative imaging in oncology clinical trials.Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Future directions in the treatment of osteosarcoma.Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Can Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Be Used As a Useful Method to Evaluate the Treatment Response to Neoadjuvant Therapy Combined With Sorafenib and Anti-VEGF in Children Diagnosed With Metastatical Bone Sarcoma?Alternative formulations of sorafenib for use in children.Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma.Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.Safety and feasibility of targeted agent combinations in solid tumours.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.

P2860

Q21285014-488AC028-BE67-4956-9CDF-30F0ECC95030 Q26746205-64F6B24B-F0C4-44CC-B961-A7895720FD72 Q26797555-B6D2D35F-A17F-4056-8F2D-EAE6D198C183 Q27003304-96B5A136-0C66-4EED-9B3A-72B45A9743FB Q28067644-B3C2989E-54E6-48CE-88D1-CF513AEE8870 Q28077590-C3655B5D-423A-420C-871F-6594C45812C6 Q28082793-79E88838-E667-4C57-9644-B81E22152297 Q28550228-0B14B4AC-492C-4B33-A476-5E995794D96E Q28817274-92BEAEF7-22AD-454E-A950-DBDBB44D981E Q31018689-A70039B5-6094-448E-ABEF-F4E9E4520D39 Q33408668-A73A01BA-9A14-4284-8164-2BEF16AD067C Q33428775-9CAC35F1-6BEE-4020-9FD1-FFCA30DEC0C5 Q33597266-DF07C4D2-E206-49DD-8B61-712410C505F7 Q33725511-DFF97388-76CF-42AA-9187-006A95714D76 Q33805555-6D9B7BAE-D98A-4204-9DFB-25D316D7D80F Q33835657-F0A6D512-5F55-49BC-918D-ADC1AD8CF7EC Q33917772-E6EFE16F-2930-4DFE-9831-9AAB8EAE7E3B Q34272887-5F7145B0-5CD5-4A36-802D-36A1E3BC66B9 Q34436450-901CEAED-38CE-43F4-A821-08CF0DDBD1A9 Q34660607-48250CC7-88E4-4781-85C4-298A3E06475E Q35987375-E784408A-8E6F-45E4-85B8-4FB6C1326BEC Q35995283-1E1316D7-FDA6-4593-9BA9-270F1D370F21 Q36097737-EA832826-C65D-4D53-807B-D5B6FB380D3E Q36166394-4DE3D80F-2963-4F32-AD40-0CD60F70E262 Q36270115-77683866-D5AA-42C9-899E-0E8DDCE9A2A2 Q36303765-4C4E9387-0BF0-4DFB-9B8A-296FFC303E17 Q36316518-6328EDD2-4460-460C-8157-9D2530925074 Q36356334-B4DC5C26-02A9-4F40-A1C0-8745CCBBFBE9 Q36511158-A38D4869-8015-47D2-845F-3C1DF2C83A12 Q36600800-1CEE2E06-AADD-4452-A27C-E5A6A2D3679E Q36846801-8E5DAEC6-B5AC-4CDA-8872-960ABB686D33 Q36888962-FBB10389-0BC2-4F02-B993-11F78533502D Q36996436-C383E025-C2BD-46ED-9E8F-B6EE5D6BB205 Q37239947-AA95477E-FFE4-4D79-BC4B-A252D385966F Q37481150-868120E1-540F-4159-A791-DE7DFAED548E Q37944599-EBA6FF83-3591-45D8-B26F-F878BBE20769 Q38011606-08B29404-10DB-4604-9564-AEA63B442F33 Q38077440-4BB95FE0-D526-442D-867D-1BDD22E2B391 Q38103397-D7AFFB28-560F-4C6A-8561-C1D28A95C210 Q38120777-2A1F8D22-1FD0-4F5C-AF91-FA290254845B

P2860

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

http://www.wikidata.org/entity/Q34628840

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@ast

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@en

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@nl

type

label

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@ast

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@en

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@nl

prefLabel

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@ast

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@en

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@nl

P1433

Q34628840-4DC1551E-AF1A-490B-8336-F997BB2C7DD5

P1476

Q34628840-8CF0BFC8-5C8B-438E-ABDE-069AF68C242C

P2093

Q34628840-1999C331-5CD4-4086-B1D5-81C894DC5E7C

Q34628840-1E4319BA-32B2-4434-AF6A-8A8B4CD33879

Q34628840-2BEAEA22-F489-4F73-9A6A-9A0A78F306DB

Q34628840-4C7BE9B3-899A-4E38-A042-E909B3AA3224

Q34628840-510681B0-7A7A-49BC-9F28-EBF6B5DAD819

Q34628840-6EC723A5-6784-48D7-A6EE-ECC7AFB5B71F

Q34628840-873AE7F1-1534-43BA-AD17-824BBC4A524C

Q34628840-8A42CE70-8307-45A8-A32B-D958CC6C2764

Q34628840-8C2DC7C1-A9B5-4B36-ADD8-6E3750BE08AD

Q34628840-9DD068DF-6322-4F90-B652-1935EDDE68BD

P2860

Q34628840-3149F33D-CE77-4A9B-A134-EBD6D198BCB7

Q34628840-32E13EFD-DCE7-4043-BE9D-AB36089AA4C8

Q34628840-36606F8A-9E8A-4989-869D-2DE359107949

Q34628840-3733D542-A76E-4DEB-B21A-BC300B8F5FC5

Q34628840-458918DB-8208-41CB-9A65-A542E08EA045

Q34628840-4E8B5043-9A89-4F91-A1EF-E943CEC6D519

Q34628840-50DC3A5C-2BFC-443A-B033-15C905C18D99

Q34628840-598A0094-55DE-41A3-A5B5-6075668D784B

Q34628840-68DD8CE7-5CE5-455C-BE62-B59FF7C5DB0D

Q34628840-6DF7D0BF-61C9-401D-960B-31292EE43B62

P304

Q34628840-CDFA7781-CBB0-476E-9585-4BD1D08D1FE9

P31

Q34628840-CF1082C0-B667-4C3D-84B6-DCC757B35766

P356

Q34628840-4EC7F87F-AFF4-4BF9-8CBF-06B5DB7D55BF

P433

Q34628840-7472229E-5704-4F9C-9D7D-64F31E83E202

P478

Q34628840-C53FD5D5-1F2A-4B39-8C14-D7059EE6783B

P577

Q34628840-5A249C6B-FAB7-45A6-98C4-8435DD66B0AB

P698

Q34628840-183E694B-8950-4635-A4DB-3EAB6DDFFB30

P921

Q34628840-0B108230-26BD-4DE3-8B72-3E46EBD5B435

Q34628840-6E82BB64-47A9-45FD-AC32-E094FC4A0A6A

P356

P1433

Annals of Oncology

P1476

A phase II trial of sorafenib ...... n Italian Sarcoma Group study.

@en

P2093

E Palmerini

http://www.w3.org/2001/XMLSchema#string

F Fagioli

http://www.w3.org/2001/XMLSchema#string

G Grignani

http://www.w3.org/2001/XMLSchema#string

L D'Ambrosio

http://www.w3.org/2001/XMLSchema#string

M Aglietta

http://www.w3.org/2001/XMLSchema#string

M Mercuri

http://www.w3.org/2001/XMLSchema#string

P Dileo

http://www.w3.org/2001/XMLSchema#string

P G Casali

http://www.w3.org/2001/XMLSchema#string

P Picci

http://www.w3.org/2001/XMLSchema#string

S D Asaftei

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.

P304

508-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDR151

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21527590

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial